Abstract
Use of drug-coated balloon (DCB) in de novo lesions is usually preferred in small vessels, and the recently reported Basket small 2 trial showed that DCBs were noninferior to second-generation DES. All the available data DCBs in de novo lesions have been extrapolated from paclitaxel-eluting balloons
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
